Obermatt
See Similar Stocks →

Inter Pharma

SET:IP · TH9474010005
Personal ProductsSmall

360

59
Medium confidence — indicative
EV / EBIT14
Price / Owner Earnings7
Owner Earnings Yield30
Dividend Yield1
Price/Sales74
EV / Gross Profit45
Price/Book72
Return on Capital45
Cash Return on Capital30
Return on Equity39
EBIT Margin60
Gross Profitability37
Cash Conversion86
Accruals43
Owner Earnings Margin28
Sales growth65
Profit Growth83
Long-Term EPS Growth67
Reinvestment23
Price momentum93
Debt load52
Refinancing78
Debt Payback35
Liquidity47
Analyst ratings—
Expectations trend—
Market mood49
Value Creation14/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Inter Pharma generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryThailand
IndustryPersonal Products
SizeSmall
TypePublic Company
ExchangeSET
Founded2006
Employees9
Websiteinterpharma.co.th
ISINTH9474010005
Last UpdateApr 2, 2026
Indices
SET (Thailand)
Themes
LivestockCardiovascularNutraceuticalNeurologyVaccinesPet Food and SuppliesHealth CareHealth DiagnosticsManufacturingMedicalPharmaceutical

Description

Inter Pharma Public Company Limited is principally engaged in the import, manufacture, and distribution of drugs and dietary supplements for both humans and animals. Business Segments The company operates through Human Healthcare, Animal Healthcare…

Analysis

Hope premium

Inter Pharma Public Company Limited is priced well ahead of what the underlying numbers justify, a pattern we describe as a hope premium.

On valuation, the picture is expensive. The owner-earnings multiple stands at 40.8×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 14/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

Similar Stocks

The companies this stock is ranked against.

Compare Inter Pharma with its peers
Dabur India
NSI:DABUR
49
CountryIndia
IndustryPersonal Products
SizeLarge
Full Stock Analysis →
Zydus
NSI:ZYDUSLIFE
22
CountryIndia
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Theravance Biopharma
NMQ:TBPH
87
CountryCayman Islands
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Industri Jamu dan Farmasi Sido Muncul
JKT:SIDO
89
CountryIndonesia
IndustryPersonal Products
SizeMedium
Full Stock Analysis →
Jubilant Life Sciences
NSI:JUBLPHARMA
47
CountryIndia
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Alembic Pharmaceuticals
NSI:APLLTD
51
CountryIndia
IndustryPharmaceuticals
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →